Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13375827 | 1.00 | SLC29A1 (0.52) | SLC29A1ADORA1ADORA3ADORA2AHIF1A | |
| SCHEMBL13930566 | 1.00 | SLC29A1 (0.52) | SLC29A1ADORA1ADORA3ADORA2AHIF1A | |
| SCHEMBL16417877 | 0.90 | ADORA1 (0.42) | SLC29A1ADORA1ADORA3ADORA2B | |
| SCHEMBL16244658 | 0.89 | SLC29A1 (0.52) | SLC29A1ADORA1ADORA3ADORA2AHIF1A | |
| SCHEMBL13375773 | 0.88 | ADORA1 (0.44) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL13213544 | 0.88 | ADORA1 (0.39) | SLC29A1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL13930534 | 0.88 | ADORA1 (0.39) | SLC29A1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL13930530 | 0.87 | SLC29A1 (0.46) | SLC29A1ADORA1ADORA3ADORA2AHIF1A | |
| SCHEMBL13375777 | 0.87 | SLC29A1 (0.46) | SLC29A1ADORA1ADORA3ADORA2AHIF1A | |
| SCHEMBL12724727 | 0.87 | TYMP (0.46) | SLC29A1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090053710-A1 | FUNCTIONAL MOLECULE, FUNCTIONAL MOLECULE SYNTHESIZING AMIDITE AND TARGET SUBSTANCE ANALYSIS METHOD | FUJITSU LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053710-A1 | FUNCTIONAL MOLECULE, FUNCTIONAL MOLECULE SYNTHESIZING AMIDITE AND TARGET SUBSTANCE ANALYSIS METHOD | TACR1, TACR2, ATIC | SLC29A1 607/4885ADORA1 51/4885ADORA3 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.